Novo Nordisk stock holds steady as Chinese approval sought for Wegovy weight-loss pill

Traders Union
All News
Financial News
Novo Nordisk slips 0.06% today

Highlights

Novo Nordisk plans to pursue regulatory approval for its Wegovy weight-loss pill in China, targeting a major new growth market after local semaglutide patent expiration.
A recent data breach affecting clinical trial participants raises potential legal and reputational risk during ongoing share buybacks totaling DKK 5.27 billion.
NVO/USD is expected to trade between $42.19 and $45.51 with mixed momentum signals and moderate seller pressure dominating intraday action.

Regulatory push in China and share buybacks offset by data breach risks

Novo Nordisk's intention to seek regulatory approval in China for its Wegovy weight-loss pill, following the recent expiration of the semaglutide patent in the country, positions the company to access a major new market and potentially diversify its revenue base going forward. The period was also marked by a data breach involving unauthorized access to personal information from some clinical trials, leading to notifications sent to affected patients and healthcare providers, which may introduce legal and reputational risks. Additionally, the ongoing expansion of Novo Nordisk's share buyback program—now covering 0.8% of share capital and totaling nearly 19.9 million B shares repurchased for DKK 5.27 billion—helped reduce the public float and provided support for per-share metrics, though price action has remained under broader selling pressure.

Mixed momentum signals as support holds above key moving averages

On the hourly chart, NVO is currently trading below the MA-20 but remains above the MA-50, while on the daily timeframe it stays under the MA-200. The Ichimoku Kijun level at $43.74 acts as immediate support. Momentum indicators are sending mixed signals: MACD shows a strong buy, ADX reflects a buy bias, yet BBP suggests sellers are dominating intraday moves. RSI stands at 52.19, flashing a buy signal; Stoch RSI indicates oversold territory and CCI is neutral, highlighting conflicting short-term momentum readings.

Range-bound trade likely as breakout probabilities appear balanced

Over the coming trading days, NVO is expected to fluctuate within the $42.19 to $45.51 range, capturing the asset's typical volatility band relative to current levels. The forecast assigns a 62% probability to a move higher and a 38% chance of a decline, with the base expectation being continued range-bound trade. A break above resistance would favor an upward scenario, while a drop below the immediate support may open the way to additional losses.

Anton Kharitonov, expert at Traders Union, sees Novo Nordisk caught between opportunity and risk. He notes that the approach to Chinese regulatory approval is promising, but the recent data breach acts as a sentiment drag. Technical signals are mixed, and with price stuck between key moving averages, the setup lacks strong upside conviction. "Until shares clear $45.51 resistance with momentum, I remain cautious and prefer to stay on the sidelines."

Previously it was reported that Novo Nordisk's stock was consolidating, with mixed technical momentum signals and uncertainty around the prospect of a near-term breakout. The current analysis adds greater weight to this outlook by spotlighting new regulatory and operational developments, making it crucial for investors to monitor how upcoming moves toward key technical thresholds may be shaped by evolving news catalysts and sentiment shifts.

Source of Data: NVO Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.